Article Text

Download PDFPDF

Intravenous injection of a modified vaccinia ankara virus induces intratumoral CD8+ lymphocyte infiltration favoring tumor control in an orthotopic tumor model upon combinatorial treatment with a TLR9 agonist
  1. Laetitia Fend1,
  2. Tanja Gatard-Scheikl2,
  3. Jacqueline Kintz2,
  4. Murielle Gantzer3,
  5. Emmanuelle Schaedler1,
  6. Karola Rittner1,
  7. Sandrine Cochin1,
  8. Sylvie Fournel4 and
  9. Xavier Préville2
  1. Aff1 grid.420228.e0000 0004 0638 2273Transgene France
  2. Aff2 grid.420228.e0000 0004 0638 2273Transgene Illkirch-Graffenstaden Cedex France
  3. Aff3 Transgene Gambia
  4. Aff4 grid.11843.3f0000 0001 2157 9291CNRS-Université de Strasbourg Illkirch Graffenstaden cedex France

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


There are many critical steps for the clinical efficacy of antigen-specific T cell-based immunotherapies among which traffic to and access to tumor beds of effector T cells, are the most limiting [1]. Preclinical research most often uses ectopic mouse tumor models for the readout fastness and easiness provided by such models. However, those models may not be the optimal way to address the issue of targeting effector T cells to a deep organ born tumor.


We set up an orthotopic preclinical model in which renal carcinoma cells (RenCa) expressing the human mucin 1 tumor-associated xeno-antigen are injected into the sub-capsular space of kidney in BALB/c mice. We then evaluated the impact of the route of injection on the therapeutic efficacy of a Modified Vaccinia virus Ankara expressing the human mucin 1 xeno-antigen (MVA-MUC1).


We show that intravenous administration of MVA-MUC1 is therapeutically superior to subcutaneous injection. Therapeutic efficacy of MVA-MUC1 can be further enhanced by intravenous administration of a TLR9 ligand (ODN1826). Substantial and necessary infiltration of tumor-bearing kidneys by CD8+ lymphocytes is associated with therapeutic protection. We observe that infiltration of CD8+ lymphocytes is not limited to tumor-bearing kidneys and is also detected in naive kidneys, liver and lungs. Kidney infiltrating lymphocytes are characterized by an effector memory phenotype and express PD-1 and Tim3 immune checkpoints molecules. Biodistribution experiments indicate that MVA encoded antigens quickly reach deep organs and in particular APC from the spleen upon i.v. injection of MVA in comparison to s.c. injection, resulting in a faster generation of MUC1 specific CD8+ T cells. Unexpectedly, addition of ODN1826 to MVA-MUC1 immunization does not result in an increase in the frequency of MUC1 specific T cells detected in the spleen. Instead, ODN1826 was associated with a more pronounced modification of the tumor microenvironment towards a TH1 type inflammatory response and a recruitment of activated lymphocytes.


Intravenous injection of MVA-MUC1 is associated with therapeutic efficacy and deep organ infiltration by MUC1-specific CD8+ T cells in an orthotopic model of renal carcinoma. This therapeutic efficacy can be further increased through the use of ODN1826. This study supports the clinical evaluation of MVA-based immunotherapies via the intravenous route.


  1. 1.